Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing
09 janv. 2025 10h00 HE
|
Numab Therapeutics AG
CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and...
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity
26 nov. 2024 08h00 HE
|
35Pharma Inc.
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity
Announcing Finix’s $75M Series C
24 oct. 2024 09h00 HE
|
Finix
SAN FRANCISCO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Finix, the full-stack payment processor enabling businesses to accept and send payments online and in-store, today announced it has raised $75...
Simbe Raises $50 Million in Series C Funding Led by Growth Equity at Goldman Sachs Alternatives
24 oct. 2024 06h00 HE
|
Simbe Robotics
SAN FRANCISCO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Simbe, a leading provider of Store Intelligence™ solutions, today announced the closing of a $50 million Series C equity financing round led by...
Oshi Health Raises $60M Series C to Strengthen Its Position as the Category Leader for Virtual Digestive Care
16 oct. 2024 08h00 HE
|
Oshi Health
Oshi Health Raises $60M Series C to Strengthen Its Position as the Category Leader for Virtual Digestive Care
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
17 sept. 2024 04h00 HE
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
22 août 2024 09h00 HE
|
Tevogen Bio Inc
WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
10 juil. 2024 03h00 HE
|
HepaRegeniX GmbH
Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regenerationElias Papatheodorou moves from Chair of the Board to CEO of...
Alumis Announces Upsized $259M Series C Financing to Advance Clinical-stage Pipeline of Oral Therapies Designed to Address Immune Dysfunction
06 mars 2024 08h00 HE
|
Alumis Inc
– Financing led by Foresite Capital, Samsara BioCapital and venBio Partners with participation from additional new and existing investors – – Proceeds will support ongoing comprehensive mid to...
Yalo secures USD$20 million investment and strategic partnership to lead the AI-Driven commerce revolution
13 déc. 2023 07h00 HE
|
Yalo
Yalo secures $20M from Glisco Partners for AI-driven commerce revolution, enhancing personalized marketing for 2.6M+ merchants in Latin America.